Quick Answer
Scinai Immunotherapeutics Ltd. reported Total Revenue of $658.0 thousand for fiscal year 2024.
Scinai Immunotherapeutics Ltd. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $658.0K | — | — | — | — | — |
| Net Income | $4.80M +173.8% |
-$6.50M -12.1% |
-$5.80M +29.4% |
-$8.21M | — | — |
| Diluted EPS | — | $0.00 -60.0% |
$0.01 +150.0% |
-$0.02 | — | — |
| Total Assets | $13.45M -23.0% |
$17.47M -35.4% |
$27.07M -15.5% |
$32.04M -43.7% |
$56.91M -50.8% |
$115.75M +9.4% |
| Cash and Equivalents | $1.96M -59.7% |
$4.87M -65.4% |
$14.07M -19.0% |
$17.37M | — | — |
| Stockholders Equity | $9.98M +318.4% |
-$4.57M -159.6% |
-$1.76M -279.2% |
$982.0K +106.5% |
-$15.04M | — |
| R&D Expense | $5.53M +6.2% |
$5.21M -9.6% |
$5.76M +77.4% |
$3.25M -93.7% |
$51.46M -25.0% |
$68.64M -4.5% |
| Operating Income | -$8.64M +11.0% |
-$9.71M +12.3% |
-$11.06M -1.8% |
-$10.86M | — | — |
| Gross Profit | -$580.0K | — | — | — | — | — |
| Shares Outstanding | 3.41B +83.7% |
1.86B +87.7% |
989.29M +33.9% |
739.05M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | March 31, 2023 | -$3.52M | -42.0% | -42.0% |
| Diluted EPS | March 31, 2023 | -$0.00 | +0.0% | +0.0% |
| Total Assets | March 31, 2023 | $23.29M | — | -13.9% |
| Cash and Equivalents | March 31, 2023 | $10.80M | -29.8% | -23.3% |
| Stockholders Equity | March 31, 2023 | -$4.81M | -458.0% | -173.3% |
| R&D Expense | March 31, 2023 | $2.00M | +71.5% | +71.5% |
| Operating Income | March 31, 2023 | -$3.19M | -21.8% | -21.8% |
| Shares Outstanding | March 31, 2023 | 1.31B | — | +32.8% |
- Scinai Immunotherapeutics Ltd. reported Total Revenue of $658.0 thousand for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. reported Net Income of $4.80 million for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. showed an increase of +173.8% in Net Income compared to the prior fiscal year.
- Scinai Immunotherapeutics Ltd. reported Diluted EPS of $0.00 per share for fiscal year 2023.
- Scinai Immunotherapeutics Ltd. showed a decrease of -60.0% in Diluted EPS compared to the prior fiscal year.
- Scinai Immunotherapeutics Ltd. reported Total Assets of $13.45 million for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. showed a decrease of -23.0% in Total Assets compared to the prior fiscal year.
- Scinai Immunotherapeutics Ltd. reported Cash and Equivalents of $1.96 million for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. showed a decrease of -59.7% in Cash and Equivalents compared to the prior fiscal year.
- Scinai Immunotherapeutics Ltd. reported Stockholders Equity of $9.98 million for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. showed an increase of +318.4% in Stockholders Equity compared to the prior fiscal year.
- Scinai Immunotherapeutics Ltd. reported R&D Expense of $5.53 million for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. showed an increase of +6.2% in R&D Expense compared to the prior fiscal year.
- Scinai Immunotherapeutics Ltd. reported Operating Income of -$8.64 million for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. showed an increase of +11.0% in Operating Income compared to the prior fiscal year.
- Scinai Immunotherapeutics Ltd. reported Gross Profit of -$580.0 thousand for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. reported Shares Outstanding of 3.41 billion shares for fiscal year 2024.
- Scinai Immunotherapeutics Ltd. showed an increase of +83.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: